The FDA’s GenAI proposal: evolving regulation for an evolved medtech era
The FDA's discussion paper around a proposed approach to GenAI-based medech regulation is open to stakeholder feedback until 19 October 2026.
Accelerate decision-making with data-led confidence
Combine proprietary data, human expertise, and purpose-built AI to uncover insights and accelerate better business decisions.
Discover our solutions
Drug delivery’s next bottleneck isn’t innovation, it’s industrial capacity
Australia starts investigation into OpenAI Medicare breach
Industry partnership will determine the success of the transition to low-GWP pMDIs
UK government champions healthtech through new NHS access programme